Abstract
Clinical checklists are the current gold standard to determine whether a child with cancer shows indications for genetic testing. Nevertheless, the efficacy of these tests to reliably detect genetic cancer predisposition in children with cancer is still insufficiently investigated. Here, we assessed the validity of clinically recognizable signs to identify cancer predisposition by correlating a state-of-the-art clinical checklist to the corresponding whole exome sequencing analysis in an unselected single-center cohort of 139 child-parent datasets. We applied a strict testing to only include autosomal dominant or compound heterozygous cancer-related variants.
Our study reflects a high consent rate for genetic testing (>90%). In total, 1/3rd of patients had a clinical indication for genetic testing according to current recommendations and 10.8% (n=15/139) of children harbored a proven cancer predisposition based on exome sequencing. Out of these only 73.3% (n=11/15) were identified through the clinical checklist. In addition, >2 clinical findings in the applied checklist increased the likelihood to identifying genetic predisposition from 15% to 50%. While our data revealed a high rate of genetic predisposition (50%, n=5/10) in Myelodysplastic Syndrome (MDS) cases, no cancer predisposition variants were identified in the sarcoma and lymphoma group.
In summary, our data showed a low checklist specificity of 68.5%, and missed every 4th child with genetic predisposition. This highlights the drawbacks of sole clinical evaluation to accurately identify all children at risk and underlines the need for routine germline sequencing of pediatric cancers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
J.H. is supported by ERC Stg 85222 PreventALL, ERA Per Med.JTC 2018 GEPARD, Deutsche Kinderkrebshilfe (DHK) Excellenz Foerderprorgamm fuer etablierte Wissenschaftlerinnen und Wissenschaftler 70114539, and Sonnenstrahl e.V. Dresden, Foerderkreis fuer krebskranke Kinder und Jugendliche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Technical University Dresden (TUD) gave ethical approval for this work (Ethical Vote EK 181042019)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
(Likely) Pathogenic variant identified in the study were submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). The raw datasets generated during and/or analyzed during the current study are not publicly available due to personal data restrictions but are available from the corresponding authors on reasonable request.
